Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 60% of total revenue is derived from sales of large joints, another 22% comes from extremities and trauma; the remaining portion is primarily related to spine and dental products.
| Website: | www.zimmerbiomet.com |
| Email: | derek.davis@zimmerbiomet.com |
| Main Phone: | +1 574 267-6131 |
| Address: | 345 East Main Street |
| State: | IN |
| City / Town: | Warsaw |
| Country: | USA |
| Postal Code: | 46580 |
| Exchange: | NYE |
| CEO: | Bryan C. Hanson |
| Employees: | 19000 |
| NAICS: | Surgical Appliance and Supplies Manufacturing(339113) |
Wi-Fi 6 is the next generation of wireless Wi-Fi. Combined with 5G this will be a powerful dynamic-duo for investors, users and workers who know which companies to focus on.
Tired of big banks? Going small may be the way to go.
The company remains under the radar, but it may soon be a different story.
Here's why many consider Oppenheimer the number one trusted research name out there today.
Five Prime Therapeutics (FPRX), a biotechnology company, releases its overwhelming positive Q2 2016 financial and operational report.
These out-of-favor stocks are may just be ripe for activist investors.
Is it possible to predict market collapses?
Recent stock market volatility is an opportunity for biotech investors to pick up great stocks before market caps rise substantially. In this interview with The Life Sciences Report, Michael King
Volatility is the nature of the biotech beast, and it must be tamed or utilized to advantage. That's the philosophy of Eden Rahim, portfolio manager and option strategist at Theta Strategies
It's all about the fundamentals for Jason Napodano, CFA, of Zacks Investment Research. Revenue and earnings at the big biotechs are signaling investors that the market is still strong, and
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 60% of total revenue is derived from sales of large joints, another 22% comes from extremities and trauma; the remaining portion is primarily related to spine and dental products.
| Website: | www.zimmerbiomet.com |
| Email: | derek.davis@zimmerbiomet.com |
| Main Phone: | +1 574 267-6131 |
| Address: | 345 East Main Street |
| State: | IN |
| City / Town: | Warsaw |
| Country: | USA |
| Postal Code: | 46580 |
| Exchange: | NYE |
| CEO: | Bryan C. Hanson |
| Employees: | 19000 |
| NAICS: | Surgical Appliance and Supplies Manufacturing(339113) |
Wi-Fi 6 is the next generation of wireless Wi-Fi. Combined with 5G this will be a powerful dynamic-duo for investors, users and workers who know which companies to focus on.
Tired of big banks? Going small may be the way to go.
The company remains under the radar, but it may soon be a different story.
Here's why many consider Oppenheimer the number one trusted research name out there today.
Five Prime Therapeutics (FPRX), a biotechnology company, releases its overwhelming positive Q2 2016 financial and operational report.
These out-of-favor stocks are may just be ripe for activist investors.
Is it possible to predict market collapses?
Recent stock market volatility is an opportunity for biotech investors to pick up great stocks before market caps rise substantially. In this interview with The Life Sciences Report, Michael King
Volatility is the nature of the biotech beast, and it must be tamed or utilized to advantage. That's the philosophy of Eden Rahim, portfolio manager and option strategist at Theta Strategies
It's all about the fundamentals for Jason Napodano, CFA, of Zacks Investment Research. Revenue and earnings at the big biotechs are signaling investors that the market is still strong, and
| Last Price 148.53 | Change $ 0.91 | Change % 0.62 | Tick N/A |
| Bid N/A | Bid Size 0.00 | Ask N/A | Ask Size 0.00 |
| Open 148.07 | High 149.63 | Low 147.78 | Prev Close 147.62 |
| Last Trade | Volume 760,634 | 52 Wk Hi 150.79 | 52 Wk Low 96.99 |
| Market Cap 30.6 bi | Ex-Div Date | Div Rate 0.96 | Yield 0.6460 |
| Shares 205,684,362.00 | EPS (TTM) -0.48 | PE Ratio N/A | Exchange NYSE |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 5 | 32 |
| Number of Buys | 2 | 17 |
| Number of Sells | 3 | 15 |
| Net Activity | -117 | 46837 |
| Last 10 Buys | Shares |
|---|---|
| Bryan C. Hanson | 1,000 |
| Bryan C. Hanson | 1,000 |
| Bryan C. Hanson | 1,000 |
| Bryan C. Hanson | 1,000 |
| Arthur J. Higgins | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Katarzyna Mazur-Hofsaess | 1,000 |
| Tony W. Collins | 1,000 |
| Tony W. Collins | 1,000 |
| Chad F. Phipps | 1,000 |
| Chad F. Phipps | 1,000 |
| Daniel E. Williamson | 1,000 |
| Tony W. Collins | 1,000 |
| Tony W. Collins | 1,000 |
| Tony W. Collins | 1,000 |
| Tony W. Collins | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 158 | 158 | 158 | 158 |
| Low Target Price Estimate | 110 | 110 | 110 | 110 |
| Mean Target Price Estimate | 134.05 | 134.05 | 134.05 | 134.05 |
| Standard Deviation | 11.21 | 11.21 | 11.21 | 11.21 |
| Date of Most Recent Estimate | 05/01/18 | 05/01/18 | 05/01/18 | 05/01/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-11 |
| SD | Specialized Disclosure Report | 12 | 2018-05-31 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-23 |
| 8-K | Report of unscheduled material events or corporate changes. | 3 | 2018-05-21 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-17 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-17 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-17 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-17 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-17 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-17 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 16 | 17 | 16 | 18 |
| Moderate Buy | 1 | 1 | 1 | 1 |
| Hold | 7 | 7 | 7 | 5 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1.63 | 1.6 | 1.63 | 1.46 |
© 2019 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).
Gathering Data... Please wait